Brief Summary of Minutes of Annual Meeting

ACCOMPLISHMENTS FROM THE REGIONS AND NEW PROJECTS: Northeastern  Dr. Paul R. Bowser Progress of the work and principal accomplishments: Hydrogen Peroxide Project: INAD 9493 Hydrogen Peroxide as a Therapeutic Compound for Bacterial Gill Disease in Fish. No additional work has been performed on this project during this study period. Species Grouping Project: INAD 10-320 Oxytetracycline in Fish INAD 10-823 Romet-30 in Fish INAD 11-145 Florfenicol in Fish A primary constraint in the availability of therapeutic compounds for the Aquaculture Community is the relatively large number of fish species that are currently cultured or that have significant potential as commercial species. Currently, research in support of a label for a therapeutic compound must be performed separately for each species for which the label is desired. We have undertaken a project designed to show the similarities in how drugs are handled by different fish species with the goal of supporting a species (crop) grouping concept for fish. We have conducted these studies in a collaborative effort with the Western Region NRSP7. Within this context, to date we have completed the following preliminary Human Food Safety/Tissue Depletion Studies using the following test articles as model compounds: Oxytetracycline: 1. Walleyes, freshwater fish, 15C and 20C 2. Tilapia, freshwater fish, 25C and 30C 3. Hybrid Striped Bass, saltwater fish, 20C and 25C 4. Summer Flounder, saltwater fish, 17C and 20C 5. Rainbow Trout, cold water trial (8C) Romet-30: 1. Walleyes, freshwater fish, 20C and 25C 2. Tilapia, freshwater fish, 25C and 30C 3. Hybrid Striped Bass (would not accept ration; Species removed from Romet trials) 4. Summer Flounder, saltwater fish, 17C and 20C Florfenicol (10 mg/Kg/d, 10d): 1. Walleyes, freshwater fish, 20C and 25C 2. Tilapia, freshwater fish, 25C and 30C 3. Hybrid Striped Bass, saltwater, 20C, 25C Florfenicol (Effect of fish size) 1. Tilapia  100 gm, freshwater fish, 25C, 15 mg/Kg, 10d 2. Tilapia  250 gm, freshwater fish, 25C, 15 mg/Kg, 10d 3. Tilapia  500 gm, freshwater fish, 25C, 15 mg/Kg, 10d Several attempts were made to conduct human food safety studies for Romet-30 in hybrid striped bass. Additional trials where the new Romet-TC was used were also met with a lack of palatability. Therefore, we will not include hybrid striped bass in our efforts with Romet. Usefulness of the findings: In all cases, the findings of these projects serve as the foundation for continued work on these compounds. The Human Food Safety Studies completed to date in fish are consistent with what was expected; namely that the elimination of therapeutic compounds from the edible portion of the fish tested are within the withdrawal times currently specified for labels, or available in the literature for oxytetracycline, Romet-30 and Aquaflor (Florfeniol) in trout, salmon and catfish. Work planned for next year: Species Grouping Project: INAD 10-320 Oxytetracycline in Fish INAD 10-823 Romet-30 in Fish INAD 11-145 Aquaflor (Florfenicol) in Fish Future work is being hampered by a lack of funds in the Northeast Region. Should funding become available, we propose to conduct Efficacy Studies of oxytetracycline in a collaborative effort with the New York State Department of Environmental Conservation. The particular focus of the efficacy trials will be for the treatment of bacterial diseases not currently on the label for treatment of bacterial diseases of cool water species such as walleyes, muskellunge and tiger muskellunge (hybrid muskellunge X northern pike). These studies will be initiated when diagnosed field cases can be identified that will lend themselves to the implementation of controlled field studies. Other: We are also considering the development of a project that centers on the question of disinfection of fish eggs to prevent the vertical transmission of Viral Hemorrhagic Septicemia Virus. Publications issued or manuscripts approved during the year: (see Principal Publications at end of report) CRITICAL REVIEW (Northeast Region) 1) Work accomplished under the original project: The original objectives of the project were to conduct a national program to obtain minor and specialty animal-drug clearances (tolerances, exemptions and registrations) in cooperation with state, federal and industry personnel. The mission of NRSP-7 is: To identify animal drug needs for minor species and minor uses in major species. To generate and disseminate data for safe and effective therapeutic applications, and To facilitate FDA/CVM approvals for drugs identified as a priority for a minor species or minor use. Under the framework of this mission, progress has been made in the following areas: (A) Use of hydrogen peroxide for the control of bacterial gill disease in fish. Target animal safety studies have been completed in both rainbow trout and walleye. Information collected during these studies constituted the subject of eight manuscripts in the peer-reviewed literature and several presentations at scientific meetings. Our raw data and a peer reviewed publication (see Saez and Bowser 2000 below) describing discharge kinetics of hydrogen peroxide from a fish hatchery were provided to the U.S. Geological Survey Upper Midwest Environmental Sciences Center, La Crosse, Wisconsin, for their use in the recent submission that resulted in a label for hydrogen peroxide. We also provided reprints of our eight peer reviewed publications to the Sponsor in response to their request as they prepared their all other relevant information submission. The manuscripts provided were the following: Tort, M.J., A.J. Kuhl, G.A. Wooster and P.R. Bowser. 1998. Modification of tolerance of walleye (Stizostedion vitreum) to bath treatment with hydrogen peroxide. Journal of the World Aquaculture Society 29:499-504. Saez, J.A. and P.R. Bowser. 2000. Hydrogen peroxide concentrations in hatchery culture units and effluent during and after treatment. North American Journal of Aquaculture 63:74-78. Tripi, C.M. and P.R. Bowser. 2001. Toxicity of hydrogen peroxide to pre-exposed young-of-the-year walleye (Stizostedion vitreum): effects of water quality and age of fish. Journal of the World Aquaculture Society 32:416-421. Tort, M.J., C. Jennings-Bayshore, D. Wilson, G.A. Wooster and P.R. Bowser. 2002. Assessing the effects of increasing hydrogen peroxide dosage on rainbow trout(Onchorhynchus mykiss) gills utilizing a digitized scoring methodology. Journal of Aquatic Animal Health 14:95-103. Tort, M.J., D. Pasnik, C. Fernandez-Cobas, G.A. Wooster and P.R. Bowser. 2002. Quantitative scoring of gill pathology of walleyes (Stizostedion vitreum) exposed to hydrogen peroxide. Journal of Aquatic Animal Health 14:154-159. Tort, M.J., C. Fletcher, G.A. Wooster, and P.R. Bowser. 2003. Stability of hydrogen peroxide in aquaria as a fish disease treatment. Journal of Applied Aquaculture 14:(3/4) 37-45. Tort, M.J., G.A. Wooster and P.R. Bowser. 2003. Effects of Hydrogen Peroxide on Hematology and Blood Chemistry Parameters of Walleye (Stizostedion vitreum). Journal of the World Aquaculture Society 34:236-242 Tort, M.J., D. Hurley, C. Fernanzez-Cobas, G.A. Wooster and P.R. Bowser. 2005. Effects of hydrogen peroxide treatment on catalase and glutathione activity in walleye (Sander vitreus). Journal of the World Aquaculture Society 36(4):576-585. (B) Species Grouping in Fish INAD 10-320 Oxytetracycline in Fish INAD 10-823 Romet-30 in Fish INAD 11-145 Aquaflor (Florfenicol) in Fish Our efforts have focused on evaluation of a species grouping concept for finfish. Within this effort we have conducted Human Food Safety/Tissue Elimination Studies as follows: Oxytetracycline Tilapia (25C, 30C) - completed Walleye (15C, 20C) - completed Hybrid Striped Bass (20C, 25C) - completed Summer Flounder (17C, 20C)  completed Results of studies conducted in the above four fish species are summarized in the publication: Chen, C.-Y., R.G.Getchell, G.A.Wooster, A.L. Craigmill and P.R. Bowser. 2004. Oxytetracycline residues in four species of fish after 10-day oral dosing in feed. Journal of Aquatic Animal Health 16:208-219. Rainbow Trout, cold water trial (8C) - completed Romet-30 Tilapia (25C, 30C) - completed Walleye (20C, 25C)  completed Summer Flounder (17C, 20C)  completed Results of studies conducted in the above three fish species are summarized in the publication: Kosoff, R.E., C.-Y. Chen, G.A. Wooster, R.G. Getchell, Clifford, A.L. Craigmill and P.R. Bowser. 2007. Sulfadimethoxine and Ormetoprim Residues in Three Species of Fish After 5-day Oral Dosing in Feed. Journal of Aquatic Animal Health 19:109-115 Hybrid Striped Bass (20C, 25C) - did not accept feed medicated with Romet-30; palatability problems; two additional trials were attempted with feed medicated with Romet-TC (a product developed to avoid palatability problems). These additional studies were also unsuccessful because of lack of feed acceptance due to apparent palatability problems by the hybrid striped bass. No further work with Romet-30 or Romet-TC is currently planned. Aquaflor (10 mg/Kg/d X 10 days) Tilapia (25C, 30C) - completed Walleye (20C, 25C) - completed Hybrid Striped Bass (20C, 25C) - completed Aquaflor (15 mg/Kg/d X 10 days) Tilapia 100 gm fish - completed 250 gm fish - completed 500 gm fish - completed Results of studies conducted with Aquaflor are summarized in the following two publications that have been accepted for publication: Kosoff, R.E., C.-Y. Chen, G.A. Wooster, R.G. Getchell, A. Clifford, J.L. Craig, P. Lim, S.E. Wetzlich, A.L. Craigmill, L.A. Tell and P.R. Bowser. 2009. Florfenicol Residues in Three Species of Fish After 10-day Oral Dosing in Feed. Journal of Aquatic Animal Health. In press Bowser, P.R., R.E. Kosoff, C.-Y. Chen, G.A. Wooster, R.G. Getchell, J.L. Craig, P. Lim, S.E. Wetzlich, A.L. Craigmill, and L.A. Tell. 2009 Florfenicol Residues in Nile Tilapia After 10-day Oral Dosing in Feed: Effect of Fish Size. Journal of Aquatic Animal Health. In press Our protocol employed the optimum culture temperature for each fish species, plus one additional lower temperature at which the species might be cultured in an economically viable manner. A preliminary evaluation of our data suggests that Oxytetracycline and Romet-30 were eliminated from the edible portion of the fish at rates that will very likely be within the current label for salmonids and channel catfish. (2) The degree to which the objectives have been met: Work has focused on a number of important therapeutic compounds in aquatic animals. The work is being conducted in a deliberate manner with the goal of developing appropriate data that will be submitted in support of a label for these compounds. An initial step in this process is the publication of the data in the peer reviewed scientific literature. While we consider it extremely important to have such peer-reviewed information available for the veterinary community, should they consider an extra-label use, the ultimate goal is to secure a label for the product. As an additional goal, the work is being done in a manner that could justify a species grouping concept for finfish cultured in the United States. Additional work is currently being impacted by a lack of funds in the Northeast Region. 3) Incomplete work or areas needing further investigation: The development of a crop (species) grouping concept is seen as imperative for supporting efforts to gain labels for therapeutic compounds for fish. Our work on Oxytetracycline, Romet-30/Romet-TC and Aquaflor (Florfenicol) in fish is proposed to be part of an effort to utilize those compounds as models in this effort. We expect that our efforts in developing a species grouping concept for fish will be a major undertaking in the upcoming years. Principal Publications (during the past year): Kosoff, R.E., C.-Y. Chen, G.A. Wooster, R.G. Getchell, A. Clifford, J.L. Craig, P. Lim, S.E. Wetzlich, A.L. Craigmill, L.A. Tell and P.R. Bowser. 2008. Florfenicol Residues in Three Species of Fish After 10-day Oral Dosing in Feed. Journal of Aquatic Animal Health. In press Bowser, P.R., R.E. Kosoff, C.-Y. Chen, G.A. Wooster, R.G. Getchell, J.L. Craig, P. Lim, S.E. Wetzlich, A.L.Craigmill, and L.A. Tell. 2008. Florfenicol Residues in Nile Tilapia After 10-day Oral Dosing in Feed:Effect of Fish Size. Journal of Aquatic Animal Health.In press NORTH CENTRAL  DR. RONALD W. GRIFFITH Sheep CIDR-G Tissue Residue Study This study was performed by Dr. Dennis Hallford at New Mexico State University in cooperation with both the Western and North Central Regions. NRSP-7 was informed on January 5, 2009 that the study report had been accepted by the Office of New Animal Drug Evaluation. This completed the data package required of NRSP-7 for approval of CIDR-Gs in sheep for a zero time withdrawal period. Goat CIDR-G Milk Residue These studies are being supported by both the NC and Western Regions of NRSP-7. The in-life phase of milk residue study was performed at UC-Davis in fall 2007 and the analytical phase was performed by Dr. Hallford at New Mexico State University. The study report has been recently submitted to the FDA/CVM. The data indicate that progesterone levels in the milk of pregnant goats are greater than progesterone levels in the milk of CIDR-treated goats. Goat CIDR-G Tissue Residue Currently planned for Fall 2009. Dr. Dennis Hallford at New Mexico State University plans to perform both the in-life phase and residue analysis. Goat CIDR-G Effectiveness Re-revision of the protocol is underway. Hopefully study will begin in late summer/fall 2009. Draxxin Target Animal Safety in Goats The in-life phases of the study were completed on March 22, 2008. The tissues from the untreated control and high-dose-group goats were examined for histopathology. Some minor lesions were observed in both groups and it was decided to examine the tissues from the 1X and 3X groups just in case ONADE would want that data. All the goats remained in good health except for one untreated control goat that developed respiratory disease. A few of the goats had some scattered gross lesions that seemed to be related to infectious processes rather than any toxic effects of the drug. In addition to the TAS portion of the study, we collected tissues and plasma for tulathromycin analysis for publication purposes. Draxxin Efficacy in Goats The protocol for a natural exposure model has been accepted by CVM. However, the studies were predicted to take three to six years to complete and require a significant portion of the financial resources of the NC Region. An alternative protocol based upon determination of AUC/MIC was prepared and submitted. However, ONADE wanted us to base statistical significance by comparison to cattle AUC/MIC. We were asked to provide an alternative target for determining effectiveness. It was decided that we needed some preliminary analytical and MIC data in order to set a realistic target. We have procured and tested a small group of bacterial isolates for MICs. The MICs are very close to those described for cattle. Plasma samples were collected from 6 goats and these have been analyzed for tulathromycin levels. Draxxin Tissue Residue The protocol has been reviewed by ONADE and there were relatively few comments. The protocol was amended and sent to Scott Wetzlich (Western Region NRSP-7) who will be doing the analysis. The methods for tissue extraction and tulathromycin analysis are currently being developed and validated. This study can begin whenever assay validation is complete. We will have tissues from goats at 2-, 3-, 4- and 5-weeks post treatment for determination of a target end point for the tissue residue study. Lasalocid Efficacy in Pheasants The study was performed by Drs. Larry McDougald and Lorraine Fuller at the University of Georgia with the assistance of Dr. Thomas McQuistion from Milliken University. A draft of the final report and an associated paper for publication was received on April 16, 2008. The full study report has been received and forwarded to Sandy Ogletree at UC-Davis for QA. Lasalocid TAS in Pheasants The protocol for this study was submitted to ONADE for review and was returned in early July. Drs. McDougald and Fuller have agreed to perform this study as well. Lasalocid Human Food Safety in Pheasants The protocol for this project is being revised and the study may be conducted in 2009 if the assay is validated. Regulin (melatonin) implants for sheep No activity to report. There does not seem to be much interest in this product either from the manufacturer or the sheep and goat industry. Bioclip for Sheep No activity to report. Does not seem to be much interest. Fasinex (Triclabendazole) for Deer and Elk No Activity to report. A major obstacle is that the drug is not currently marketed for cattle in the U.S. WESTERN  DRS. LISA TELL PROGRESS OF WORK AND PRINCIPAL ACCOMPLISHMENTS: ACTIVE Regional Projects: ADR#325 - Florfenicol for sheep for respiratory disease Schering-Plough has been contacted and is interested in pursuing a bioequivalence study for the sheep using the new formulation. We are preparing to re-initiate communication with FDA/CVM to find out what is needed and possibly repeat the studies. ADR#324 - Progesterone CIDRs for Goats (TAS and Milk Residue Study) Target Animal Safety report has been accepted by FDA/CVM (February 20, 2008). Milk residue study has been completed. The final technical report was sent to FDA/CVM in December 2008. ADR#272 - Romet for Gamebirds See species grouping report. ADR#299 - Pirlimycin for Dairy Goats Project on hold until funding is identified and CIDR goat studies are completed. ADR#295 - Strontium Chloride for Salmonids. Steve Schroeder There is nothing to report. Status of the project needs to be changed. ADR#338  Spectramast" LC Sterile Suspension for Mastitis in Dairy Goats Project on hold until funding is identified and CIDR goat studies are completed. ADR#135  Erythromycin in Salmonids Mark Gaikowski with the U.S. Geological Survey (Upper Midwest Environmental Sciences Center in La Crosse, Wisconsin) is working in conjunction with NRSP-7 to revise and review specific sections of the Environmental Assessment Report for resubmission to CVM. Work continues to summarize the physical chemistry of erythromycin thiocyanate. All samples have been processed and analyzed. Because of the physical characteristics of ERTT, an empirical pKa could not be established. However, it is expected that a derived pKa will be calculated. A draft manuscript is presently in preparation. The report for the range-finding chronic toxicity study for Daphnia magna is in USGS review and should be finalized in the first quarter of 2009. A regulated chronic toxicity study will be initiated the week of Jan 26, 2009. The chronic study will provide the pivotal toxicity endpoint for the EA. The resultant final study report will likely be completed in the second quarter of 2009. ADR# 311 Lincomycin soluble powder for foulbrood disease in Honeybees Dr. Margaret Oeller is coordinating the data summary/report preparation for CVM submission. Collaborative Projects: ADR#280 - Fenbendazole in Game Birds (Pheasants, bobwhite quail, partridge) See Southern Region Report. Ms. Ogletree and Dr. Webb met in February 2008 and discussed concerns regarding the QA portion of this project. Dr. Webb will be submitting his final report to FDA/CVM in January 2009. Species Grouping Fish: See North Eastern Region Report. Sample analysis for florfenicol is complete and the two manuscripts have been accepted for publication. ADR# 235-Lasalocid in Ring-Necked Pheasants See North Central Region Report. The study director for this study was reverted back to Dr. Ronald Griffith of the North Central Region and is currently under quality assurance review (by Ms. Sandy Ogletree) for the efficacy portion of the study. ADR#324  Progesterone CIDRs for Goats: Efficacy Study See North Central Region Report. The study protocol was submitted to CVM by Dr. Griffith. The UC Davis portion of the study is to be performed in Fall of 2009. UC Davis Animal Care and Use protocol for this study has been approved. ADR#340 - Tulathromycin in Goats The plasma method was established and our laboratory analyzed 440 samples from the TAS and preliminary PK studies. Emphasis will now shift back to establishing and validating the tissue methods. At this time, the Western region is working on establishing the approved analytical method in our laboratory. Validations of liver and muscle are nearly complete. Validation of kidney is underway and fat will follow shortly. Other Projects: Avian Species Grouping Kristy Cortright finished work on the in vitro and in vivo studies. She is completing her last manuscript resulting from her PhD thesis. The manuscript should be published this year. Excede in Goats: In collaboration with Drs. Rowe and Angelos, Dr. Elizabeth Dore (UC Davis 3rd year Food Animal Resident) completed a study evaluating the use of Excede in lactating and non-lactating goats. The data from this study were compiled and presented at two scientific venues for which Dr. Dore received a resident award at one of the meetings. The serum and milk samples have been analyzed and the PK data modeled. Dr. Dore is currently working on the manuscript and the manuscript will be submitted to JVPT for publication. New Projects: Nothing to report at this time. Laboratory Report: Most of the activity continues as sample analysis in the laboratory. Results and plans are reported under separate projects above. Usefulness of the Findings: The findings from all of the studies above will be utilized to fulfill the data requirements for the FDA/CVM approval of these drugs for use in minor species. Work Planned for Remainder of the Year: This year our primary goals are to start the CIDR-G Efficacy study, continue the method validation and analyses for the goat tulathromycin project, and finish up the salmonid erythromycin environmental assessment. Obtaining CVM concurrence for a florfenicol bioequivalence study will also be a major focus. Publications issued or manuscripts approved since the last meeting: Rowe, J, Tell, L, and Wagner, D. Animal safety report on intravaginal progesterone controlled internal drug releasing devices (CIDRs) in sheep and goats. J Vet Pharmacol Therap, In Press. CRITICAL REVIEW: 1. Work accomplished under the original project The original objectives of the project were to conduct a national program to obtain minor and specialty animal drug clearances (tolerances, exemptions and registrations) in cooperation with state, federal and industry personnel to include: a. Determination and prioritization of minor-use needs and data requirements. b. Review, analysis and evaluation of minor-use research proposals. c. Development and assembly of data for minor-use registrations. d. Preparation and submission of petitions for drug registrations. Considering these objectives, considerable progress has been made towards achieving them for each of the active projects listed above, particularly in the development of the data (the actual research), its analysis, assembly and interpretation, and submission to the FDA/CVM for review. 2. The degree to which objectives have been met The degree to which these objectives have been met varies from project to project, however, in most all cases there has been progress. Those projects on which there has been no movement are reevaluated during each meeting of the NRSP-7 Technical Committee and decisions made on whether to continue to pursue them or move them into the inactive project list. 3. Incomplete work or areas needing further investigation All of the projects listed above have some work that needs to be completed before they are approved by the FDA/CVM. In some cases this is just the FDA/CVM review, while in others there is work needed by the NRSP-7 project. The NRSP-7 work which is undertaken each year within the Western Region is based on the availability of qualified and interested investigators, the capacity of the regional laboratory to validate methods and analyze samples, and cooperation of the pharmaceutical manufacturers whose products are investigated. SOUTHERN  DR. ALISTAIR I. WEBB Projects in Progress: RABBITS ADR  0107 Ivermectin & Rabbits The human safety and target animal safety reports are being prepared. This task is being treated as secondary to the fenbendazole in gamebirds. FISH ADR - 0271 Crude Carp Pituitary The project is dead with no response to FDA/CVMs concerns from the investigator. BIRDS ADR - 0280 Fenbendazole & Gamebirds The human safety report has been submitted to FDA-CVM. The concerns of UC-Davis QA resulted in (a) withdrawal of quail part of the report [QA problem with Webbs dual role as study director and QA inspector plus very problematic withdrawal conclusions; (b) letters from site personnel submitted to try and mitigate lack of in vivo QA inspection; (c) in vitro section QA was certified. The TAS report continues to be incomplete but lacks investigators final input and QA we are planning a 60-day completion. This will be submitted to FDA within 30 days. DEER ADR  0210 Fenbendazole & Red Deer & ADR  0216 Fenbendazole & Fallow Intervet / Schering Plough are still working on their combined project pipeline priorities so this project id on hold. ADR - 0294 Lasalocid and Deer / ADR - 0298 Lasalocid and Goats Problem is that Alpharma will only proceed if there is a zero withdrawal time. We are well into validating an assay and will carry out initial pilots on two deer and two goats to see if the lasalocid levels are below tolerance. See below for TAMU collaboration. The assay method has been had problems with recovery and there is no internal standard available. Once this is solved formal validation for pheasants, goats and deer will be carried out. Dr Fajt [TAMU] has sent a draft of the HFS protocol for lasalocid in goats. It is being reviewed and hopefully can soon be submitted to FDA. TAMU is developing a drug development program and will probably have its own QA unit. BEES ADR  0343 Remebee and Honey bees The Remebee project is with Beeologics for an Israel Acute Paralysis Virus [IAPV] specific double strand RNA product for prevention of collapsing colony disorder. The company has obtained an INAD and following a teleconference with FDA/CVM last month has gained both EA exclusion and approval for consumption of honey from treated hives [treatment has to end before honey flow. NRSP-7s role is of a possible advisor until FDA considers all the data submitted to determine what gaps there are and how large. Work Planned for the remainder of the Year: " Maintain lab and staff at GLP level " Submit by summer all the ivermectin for rabbit reports and the TAS in gamebirds fenbendazole reports. " Organize collaborative studies for gaining approval of fenbendazole & lasalocid in deer, and lasalocid in goats. " Prepare, in coordination with the National Coordinator, INAD submissions for studies conducted under the aegis of the Southern Region. Initial preparation of written responses to CVM review of all of the data submitted for each project. This is often a time consuming and unrecognized activity associated with the completion of each project and may require considerable correspondence and conversation. " Continued collaborative work with the other regions is anticipated and may include unplanned studies to address critical needs and opportunities to collect data. " Continue the development of the NRSP-7 web site with possible re-implementation of the RUSTi database. New / Proposed Projects: With no assured funding in sight, no new projects are under consideration with primary effort being made to complete existing studies and we are trying to collaborate with TAMU to start work on lasalocid deer & goat projects. Web Site The NRSP-7.org web has continued to function well but is need of some development such as PowerPoint Presentations. The University is cranking-up security and is centralizing control of IT. We are concerned but we have been model citizens plus we actually got our original permission to host the web site without obvious use of the ufl.edu domain from the current head of IT. The MUMSRx web database continues to be updated  it alone receives 1-2 hits each day. RUSTi is alive but with loss of biological scientist we have kept a low profile. Further development will have to wait upon programs choice of a successor on the current coordinators retirement in May 2010.

PEER-REVIEWED PUBLICATIONS (1) Spitsbergen, J. M., Blazer, V. S., Bowser, P. R., et al. Finfish and aquatic invertebrate pathology resources for now and the future. Comp Biochem Physiol C Toxicol Pharmacol 2009, 149, 249-57. (2) Wesley, I. V., Larsen, S., Hurd, H. S., McKean, J. D., Griffith, R., Rivera, F., Nannapaneni, R., Cox, M., Johnson, M., Wagner, D., and de Martino, M. Low prevalence of Listeria monocytogenes in cull sows and pork. J Food Prot 2008, 71, 545-9. (3) Smith, G. W., Davis, J. L., Tell, L. A., Webb, A. I., and Riviere, J. E. Extralabel use of nonsteroidal anti-inflammatory drugs in cattle. J Am Vet Med Assoc 2008, 232, 697-701. (4) Hurd, H. S., Brudvig, J., Dickson, J., Mirceta, J., Polovinski, M., Matthews, N., and Griffith, R. Swine health impact on carcass contamination and human foodborne risk. Public Health Rep 2008, 123, 343-51. (5) Hawkins, M. G., Taylor, I. T., Craigmill, A. L., and Tell, L. A. Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. J Vet Pharmacol Ther 2008, 31, 423-30. (6) Groocock, G. H., Grimmett, S. G., Getchell, R. G., Wooster, G. A., and Bowser, P. R. A survey to determine the presence and distribution of largemouth bass virus in wild freshwater bass in New York State. J Aquat Anim Health 2008, 20, 158-64. (7) Bartlett, S. L., Wooster, G. A., Sokolowski, M. S., Dove, A. D., and Bowser, P. R. Naturally occurring bacteraemia in American lobsters, Homarus americanus Milne-Edwards, in Long Island Sound. J Fish Dis 2008, 31, 19-25. (8) Needham, M. L., Webb, A. I., Baynes, R. E., Riviere, J. E., Craigmill, A. L., and Tell, L. A. Current update on drugs for game bird species. J Am Vet Med Assoc 2007, 231, 1506-8.